The findings come from an analysis of 787 patients enrolled in the prospective, multicenter LAANTERN study, which followed people with tumors originating in the brain as well as cancers that had spread there from other parts of the body. Patients were monitored for as long as five years after receiving treatment with the NeuroBlate system, a laser-based surgical tool developed by Monteris Medical. Washington University School of Medicine led the study at Siteman Cancer Center and coordinated participation from 24 additional sites across the United States. The results were published Aug. 17 in the Journal of Clinical Oncology, offering one of the largest evaluations to date of clinical outcomes after laser ablation for brain tumors.

LITT is designed for tumors that are recurrent, deeply located, or otherwise considered difficult to reach safely through conventional surgery. Rather than opening a large section of the skull, neurosurgeons create a small hole and insert a narrow laser probe into the brain. The probe is guided through tissue using robotic assistance and real-time magnetic resonance imaging, allowing surgeons to follow its position and monitor the temperature of surrounding structures during the procedure. Once the probe reaches the tumor, laser energy produces controlled thermal injury. The heat destroys cancer cells in the targeted region while MRI thermography helps physicians limit exposure to nearby healthy brain tissue. The procedure usually requires only a tiny incision closed with a single stitch.

The new analysis indicates that the degree of tumor destruction is not merely a technical detail but a major determinant of outcome, particularly for patients with newly diagnosed glioblastoma. Among patients whose tumors could not be removed through open surgery or had returned after previous treatment, those who achieved at least 91% tumor ablation survived a median of 2.1 years from the time of diagnosis. That figure is significant because survival following standard open surgical resection is approximately 1.5 years in comparable clinical contexts. The researchers say the data raise the possibility that laser treatment could have a role earlier in the treatment pathway for some patients, rather than being reserved exclusively for tumors that recur or cannot be accessed through conventional surgery.

The percentage of tumor destroyed is measured through imaging and reflects how completely the heated treatment zone overlaps with the cancerous tissue. A higher ablation percentage generally means that fewer viable tumor cells remain within the targeted mass, although the technique cannot eliminate every microscopic cancer cell that may have migrated beyond the visible tumor. Glioblastoma is especially challenging because its cells infiltrate surrounding brain tissue in complex patterns. Even when a visible mass is removed, invisible extensions can remain and later drive recurrence. LITT therefore does not replace radiation, chemotherapy, or other therapies in most treatment plans; instead, it can provide a focal intervention in cases where a conventional operation would carry unacceptable risks.

The study also produced a clinically important finding involving brain metastases, tumors formed when cancer spreads from another organ to the brain. The analysis focused on patients whose metastatic tumors had previously been treated with radiation and later showed signs of recurrence or treatment-related changes. Patients appeared to benefit more when laser therapy was performed while the tumors were still small. This result challenges a common watch-and-wait strategy in which doctors follow patients through several rounds of imaging to confirm that a lesion is growing before intervening. According to the findings, delaying treatment until a metastatic tumor becomes larger may reduce the potential benefit of LITT, while earlier treatment may allow the laser’s thermal field to cover a greater proportion of the tumor with less risk to surrounding brain tissue.

The procedure’s potential value extends beyond survival. Conventional craniotomy requires surgeons to temporarily remove part of the skull, and recovery can involve substantial pain, swelling, neurological monitoring, and weeks away from normal activities. By contrast, the laser procedure uses a passage only a few millimeters wide. In the LAANTERN analysis, the average hospital stay was approximately 32 hours, and most patients avoided intensive care and hospital readmission. The researchers also reported that the treatment generally preserved day-to-day quality of life and was associated with a reduced need for anti-seizure medication compared with the period before surgery. These measures matter greatly for patients with terminal or recurrent cancer, for whom maintaining independence and time at home may be as important as extending survival.

WashU Medicine researchers Eric C. Leuthardt and Albert H. Kim were among the investigators involved in the analysis. Leuthardt, the study’s principal investigator and lead author, said the work identifies factors that can help physicians select patients most likely to benefit and determine when treatment may be most effective. The study builds on more than a decade of experience with laser neurosurgery at Barnes-Jewish Hospital, part of BJC HealthCare. In 2010, Leuthardt performed the nation’s first LITT procedure for a brain metastasis at the hospital after the NeuroBlate device received clearance from the U.S. Food and Drug Administration in 2009. The program’s development was supported by early investments in intraoperative MRI, a technology that allows surgeons to visualize tissue and treatment effects during the operation rather than relying solely on scans taken before or after surgery.

Although the results are encouraging, the analysis was observational and should not be interpreted as proof that LITT is superior to open surgery for every patient with glioblastoma or metastatic disease. Treatment decisions depend on tumor size, location, shape, biological characteristics, previous radiation and chemotherapy, neurological symptoms, and the patient’s overall health. The device manufacturer, Monteris Medical, funded the study, and several investigators reported financial relationships with the company or other medical-technology and pharmaceutical organizations. Even with those considerations, the size and prospective design of the LAANTERN cohort provide unusually detailed evidence about how technical success and treatment timing influence outcomes. The researchers’ central message is that a minimally invasive laser procedure may offer its greatest benefit when physicians achieve extensive ablation and intervene before tumors become too large or too difficult to treat.

For patients facing a diagnosis that can rapidly limit both lifespan and quality of life, the prospect of returning home roughly a day after brain surgery represents a striking change from the traditional image of cancer treatment. LITT cannot cure every brain tumor, and its long-term role will require further comparative studies, but the new findings suggest that precision, timing, and careful patient selection could transform how difficult tumors are managed. By combining real-time MRI guidance with controlled thermal ablation, neurosurgeons are developing an approach that reaches deep brain lesions through a narrow path while preserving as much healthy tissue as possible. The study’s results may help move laser therapy from a last-resort option toward a more deliberately timed component of multidisciplinary brain-cancer care.

Subject of Research: People with brain tumors, including glioblastoma and brain metastases.

Article Title: Laser interstitial thermal therapy for brain tumors: a prospective multicenter analysis of 787 patients from the LAANTERN study.

News Publication Date: 17-Aug-2026

Web References: https://medicine.wustl.edu/news/lasers-help-fight-deadly-brain-tumors/ ; https://neurosurgery.wustl.edu/people/eric-c-leuthardt-md/ ; https://neurosurgery.wustl.edu/people/albert-h-kim-md-phd/

References: Journal of Clinical Oncology; LAANTERN prospective multicenter study.

Keywords: glioblastoma, brain cancer, laser interstitial thermal therapy, LITT, NeuroBlate, brain tumors, brain metastases, laser ablation, neurosurgery, MRI-guided surgery, cancer treatment, tumor recurrence, survival, minimally invasive surgery

Grade 3 astrocytomas characterized by mutations in the isocitrate dehydrogenase genes, specifically IDH1 or IDH2, present a critical therapeutic challenge due to their propensity to relapse even after aggressive multimodal interventions. The existing standard of care for newly diagnosed patients involves maximal safe surgical resection followed by radiation therapy to eliminate residual tumor cells, coupled with temozolomide—an alkylating agent that induces cytotoxicity by damaging tumor DNA and inhibiting cellular replication. However, despite these intensive treatments, tumor progression remains a significant obstacle, emphasizing the urgent necessity for targeted therapies that directly address underlying molecular aberrations.

Vorasidenib represents a novel class of brain-penetrant small molecule inhibitors specifically designed to target the neomorphic enzymatic activity of mutant IDH1 and IDH2 proteins. By selectively suppressing the aberrant production of the oncometabolite 2-hydroxyglutarate, vorasidenib aims to disrupt oncogenic signaling pathways that drive malignant transformation and tumor proliferation. The hypothesis is that combination therapy integrating vorasidenib with temozolomide could engage complementary mechanisms of action, leading to heightened cytotoxic effects, impeding tumor growth more effectively, and ultimately improving clinical outcomes for patients afflicted with this devastating disease.

The study design entails randomizing approximately 400 participants aged 12 years and older across multiple cancer centers throughout the United States into two distinct cohorts. The control group will receive radiation followed by adjuvant temozolomide coupled with a placebo for one year, succeeded by placebo monotherapy. Contrastingly, the experimental arm will undergo radiation and temozolomide combined with vorasidenib for one year, continuing with vorasidenib maintenance therapy subsequently. This bifurcated approach rigorously evaluates the additive benefits and tolerability of vorasidenib when integrated into standard treatment regimens.

Central to the investigation is the assessment of progression-free survival (PFS), a critical endpoint measuring the duration patients remain free from tumor progression or recurrence. This metric offers a sensitive indicator of therapeutic efficacy in delaying tumor resurgence. Concurrently, the trial meticulously monitors overall survival (OS) to quantify how the therapeutic adjunct influences long-term patient prognosis. Safety evaluations form an integral component, systematically documenting adverse effects and tolerability profiles to ensure that combining vorasidenib with temozolomide does not exacerbate toxicity or compromise quality of life.

IDH mutations confer a distinct metabolic and epigenetic landscape in tumor cells, generating vulnerabilities exploitable by precision medicines such as vorasidenib. These mutations cause a gain-of-function that produces the oncometabolite 2-hydroxyglutarate, which inhibits cellular differentiation and promotes oncogenic epigenetic reprogramming. Targeting this aberration represents an elegant therapeutic strategy that transcends conventional cytotoxic approaches by addressing cancer’s molecular root cause, potentially transforming the clinical management paradigm for this subset of gliomas.

Historically, targeted therapies in neuro-oncology have faced formidable hurdles due to the blood-brain barrier limiting drug delivery to intracranial tumors. Vorasidenib’s design overcomes this obstacle via enhanced CNS penetration, attaining therapeutically relevant concentrations within tumor tissue. This pharmacokinetic property is pivotal to realizing its clinical potential, as effective intracranial drug bioavailability remains a paramount determinant of success in brain cancer therapeutics.

“Despite advances in surgery, radiation, and chemotherapy, the prognosis of grade 3 IDH-mutant astrocytomas remains suboptimal, with frequent tumor recurrence driving morbidity and mortality,” explains Dr. Ugonma Chukwueke, MD, MPH, lead investigator and neuro-oncologist at the Dana-Farber Cancer Institute. “The addition of a molecularly targeted agent like vorasidenib has the potential to fill a critical treatment gap and shift the standard of care by tailoring therapy to the tumor’s genetic profile.”

This clinical trial exemplifies the broader shift in oncology towards precision medicine, where understanding the genetic and molecular underpinnings of cancer facilitates the development of specialized interventions that improve efficacy and minimize off-target toxicity. The translational approach integrates genomic insights with clinical research, fostering personalized treatment regimens that align with tumor biology and patient-specific factors.

Beyond its immediate clinical implications, the trial also aims to generate extensive biospecimen repositories and genomic data that can fuel subsequent research into resistance mechanisms, biomarkers predictive of response, and potential combination strategies. Such comprehensive data infrastructure positions the oncology community to iteratively refine and optimize therapeutic algorithms for IDH-mutant gliomas and similar malignancies.

The Alliance for Clinical Trials in Oncology, with a robust network exceeding 25,000 specialists across over 1,500 institutions, is uniquely positioned to conduct this expansive and rigorous study. Their infrastructure facilitates rapid patient enrollment, standardized protocols, and high-quality data acquisition, critical for yielding statistically meaningful and generalizable results that can influence clinical practice guidelines.

If successful, this trial could usher in the first widely adopted IDH-targeted treatment regimen embedded within the standard therapeutic landscape for grade 3 astrocytomas, offering new hope to patients and oncologists grappling with recalcitrant brain tumors. It underscores the power of integrating cutting-edge molecular therapies with existing treatment modalities to augment anti-tumor efficacy in challenging oncologic contexts.

For patients, families, and clinicians confronting the formidable diagnosis of IDH-mutant grade 3 astrocytoma, this rigorously designed trial represents a beacon of progress—advancing from generic cytotoxic therapies towards intelligent, precision-based interventions tailored to the cancer’s unique genetic architecture.

In summary, Alliance A072301 paves the way for a new era in brain tumor therapy by assessing whether the synergistic combination of radiation, temozolomide, and the novel IDH inhibitor vorasidenib can sustainably inhibit tumor growth and improve long-term survival outcomes. The results of this trial will be closely watched by the neuro-oncology community as a potential paradigm shift in the management of a historically challenging and lethal disease.

Subject of Research: Clinical trial investigating the efficacy of vorasidenib combined with temozolomide following radiation therapy in newly diagnosed grade 3 IDH-mutant astrocytoma.

Article Title: New Alliance Clinical Trial Explores Targeted IDH Inhibition Combined with Chemotherapy in Grade 3 Astrocytoma.

Web References:

• ClinicalTrials.gov Identifier: NCT07215910
• Alliance for Clinical Trials in Oncology: www.AllianceforClinicalTrialsinOncology.org

Image Credits: Dana-Farber Cancer Center

Keywords: IDH mutation, grade 3 astrocytoma, brain cancer, vorasidenib, temozolomide, radiation therapy, targeted therapy, clinical trial, progression-free survival, overall survival, neuro-oncology, precision medicine